Össur: Fine Q1 growth, No CMS reimbursement news - ABG

Fine 7% Group organic growth which could have been better
No news on CMS reimbursement, Guidance adds $4m one-off costs
Consensus a few % down on restructuring costs, growth story intact


Q1 in numbers

Embla reported fine 7% Group organic growth (Prosthetics & Neuro 10%, Braces & Support 1%), for Group sales of USD 199.9m, some 1-2% above expectations. Gross margin came in 150-170bp below expectations, but was inline when adjusting for additional $3m in cost reduction inititatives undertaken late in Q1. EBITDA pre-items came in at $33m which was 8% below ABGSC but 3% above Company collected Consensus. Net Profit came to $8.3m, 23-43% below expectations, but solid vs Consensus when adjusting for the extra cost initiatives.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2024/4/ossur---fine-q1-growth-no-cms-reimbursement-news/